CE-Ventures Backs Aptadir Therapeutics in €40 Million Seed Round, One of Europe’s Largest in Biotech
Aptadir raises €40 million in Italy’s largest biotech seed round and one of the largest in Europe
Financing will advance a novel class of RNA inhibitor-based therapeutics, including lead candidate CAP1-FMR1 for Fragile X Syndrome
Investment broadens CE-Ventures’ life sciences portfolio with an RNA therapeutics platform
Dubai, United Arab Emirates, 29th September 2026, CE-Ventures, the corporate venture capital arm of Crescent Enterprises, today announced its investment in Aptadir Therapeutics in a €40 million seed round supporting the development of the preclinical biotechnology company’s novel class of RNA inhibitor-based therapeutics for genetic disorders.
The €40 million round, the largest biotech seed financing in Italy and one of the largest in Europe, will fund Aptadir’s next stage...
